



1. CVD AND CARDIOMETABOLIC CONSIDERATIONS IN INDIVIDUALS FROM RACIAL/ETHNIC MINORITY GROUPS: AN OVERVIEW

Important Guidelines, Statements, Reports, Suggested Readings and Resources

- CMHC Webinar: "Looming Cardiometabolic Crisis: A Conversation About Race" 
- CMHC Podcast: "Ethnic and Racial Disparities in Cardiometabolic Health" with Dr. Keith C. Ferdinand 
- Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 
- Racial and Ethnic Disparities in Health and Health Care 
- Race and Ethnicity and Cardiometabolic Risk Profile: Disparities Across Income and Health Insurance in a National Sample of US Adults 
- Reducing disparities in health care 
- Minority Health 
- Inequity systemically harms people of color- ADA 



2. SPECIFIC CLINICAL CONSIDERATIONS IN RACIAL AND ETHNIC MINORITY POPULATIONS - HYPERTENSION, DIABETES, AND OBESITY

Important Guidelines, Statements, Reports Suggested Readings and Resources

- CMHC Webinar: "Cardiometabolic Health Disparities in Hispanic Americans" (+)
- CMHC Podcast: "Addressing Disparities in Obesity Management" with Dr. Fatima Cody Stanford (+)
- Association of Clinical and Social Factors with Excess Hypertension Risk in Black Compared With White US Adults (+)
- Addressing Health Disparities in Diabetes (+)
- Addressing Challenges and Implications of National Surveillance for Racial/Ethnic Disparities in Diabetes (+)
- Association of Intensive Blood Pressure Control and Living Arrangement on Cardiovascular Outcomes by Race- Post Hoc Analysis of SPRINT Randomized Clinical Trial (+)
- Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension (+)
- Obesity and Hispanic Americans (+)
- Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US Adults (+)
- Reducing racial and ethnic disparities in hypertension prevention and control: what will it take to translate research into practice and policy? (+)
- A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops (+)
- 2022 ADA Standards of Care – Improving Care and Promoting Health in Populations (+)



3. SPECIFIC CLINICAL CONSIDERATIONS IN RACIAL AND ETHNIC MINORITY POPULATIONS - HEART FAILURE AND LIPIDS


Important Guidelines, Statements, Reports Suggested Readings and Resources

- Call to Action: Structural Racism as a Fundamental Driver of Health Disparities: A Presidential Advisory from the American Heart Association (+)
- Circulation journal- focused on disparities (+)
- American Hospital Association Disparities Toolkit (+)
- The Groundwater of Racial and Ethnic Disparities Research- A Statement From Circulation: Cardiovascular Quality and Outcomes (+)
- The Triglyceride Paradox in People of African Descent (+)
- Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes (+)
- Cardiovascular disease in racial/ethnic minority populations: illness burden and overview of community-based interventions (+)
- Disparities in cardiovascular care: Past, present, and solutions (+)
- Contemporary Reevaluation of Race and Ethnicity With Outcomes in Heart Failure (+)
- Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients (+)
- Heart failure drug treatment: the fantastic four (+)
- Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans (+)
- Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement (+)
- Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry (+)



3. SPECIFIC CLINICAL CONSIDERATIONS IN RACIAL AND ETHNIC MINORITY POPULATIONS - HEART FAILURE AND LIPIDS

Important Guidelines, Statements, Reports Suggested Readings and Resources

- Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials 
- NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis 